ARECOR THERAPEUTICS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.50 GBX | 0.00% |
|
0.00% | -58.08% |
| Nov. 18 | Arecor Therapeutics names David Ellam as interim CFO | AN |
| Nov. 18 | Arecor Therapeutics Names Interim CFO | MT |
Summary: Arecor Therapeutics plc
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Arecor Therapeutics plc
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses: Arecor Therapeutics plc
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's enterprise value to sales, at 4.21 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings Chart: Arecor Therapeutics plc
Source: Surperformance
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| - | 36.57M | ||||
| 42.79B | |||||
| 36.41B | |||||
| 27.1B | |||||
| 17.58B | |||||
| - | 16.39B | ||||
| 16.46B | |||||
| 11.92B | |||||
| 10.52B | |||||
| 10.19B | |||||
| Average | 18.94B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
- Stock Market
- Equities
- AREC Stock
- Ratings Arecor Therapeutics plc